Intensity-modulated radiation therapy should be the preferred choice when treating patients with locally advanced non-small cell lung cancer, as it reduces radiation exposure to the heart and lungs, according to researchers at MD Anderson Cancer Center.
Follow-up results from the phase Ib/II CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of Rybrevant (amivantamab-vmjw)—a bispecific antibody targeting epidermal growth factor receptor and mesenchymal-epithelial transition—with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor, plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer and EGFR mutations, showed that the drug combination led to durable progression-free survival.
The phase III ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met its primary endpoint of disease-free survival at a prespecified interim analysis.
FDA granted regular approval to Gavreto (pralsetinib) for adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA-approved test.
Positive high-level results from the TROPION-Lung01 phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior therapy.
The European Commission has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%.
Preliminary results from eight patients in the phase I portion of the Acclaim-1 clinical study evaluating Reqorsa immunogene therapy (quaratusugene ozeplasmid) with Tagrisso (osimertinib) in patients with advanced, EGFR mutant non-small cell lung cancer whose disease progressed after Tagrisso showed that Reqorsa was generally well tolerated, as there were no dose limiting toxicities. Promising efficacy results were also observed.
FDA accepted the New Drug Application for repotrectinib, a next-generation tyrosine kinase inhibitor, for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer based on results from the phase I/II TRIDENT-1 trial. FDA granted the application priority review and assigned a Prescription Drug User Fee Act goal date of November 27.
The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended the approval of Opdivo plus platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at a high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%.
Positive high-level results from the FLAURA2 phase III trial showed Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
